JAK1 and acute lymphoblastic leukemia: The first inhibitor to be tested in CRLF2‐r ALL was the JAK1/2 inhibitor, Ruxolitinb.47 While this study showed a response in vivo, greater effect was observed in JAK‐activated, non‐CRLF2‐r ALL.